A build-up of fatty substances in the coronary arteries may reduce blood supply to the heart, causing coronary artery disease. To restore blood flow, a drug-eluting stent can be inserted into a ...

NICE has recommended that there is not enough evidence comparing drug-eluting stents to determine whether price variation between different stents is justified. NHS trusts should provide access to a ...

The first drug-eluting stents (DESs) were approved by the FDA in 2003, after they were shown to significantly reduce rates of restenosis and repeat revascularization, when compared with bare-metal ...

The use of drug-eluting stents (DES) has become widespread as a result of their superior revascularization rates compared with those of bare-metal stents (BMS). 1 DES are increasingly being used ...

Purpose: The mechanism of action and pharmacokinetics of sirolimus when used as part of a drug-eluting stent (DES) and the efficacy and cost of using DESs versus bare-metal stents are discussed.

Drug-eluting stents reduce the occurrence of in-stent restenosis and the need for subsequent target vessel revascularization when compared with bare-metal stents. However, drug-eluting stents may ...

The U.K. National Institute for Health and Care Excellence (NICE) opened a late-stage assessment for drug-eluting stents (DES) with an eye toward costs, advising clinicians that they should implant ...